{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:51:26Z","timestamp":1790257886273,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ygyno.2020.06.493","type":"journal-article","created":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T23:16:50Z","timestamp":1593991010000},"page":"562-569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology\/gynecologic oncology group study"],"prefix":"10.1016","volume":"158","author":[{"given":"Warner K.","family":"Huh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Fracasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don S.","family":"Dizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Charles A.","family":"Leath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Landrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"Crane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"McHale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ygyno.2020.06.493_bb0005","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2020.06.493_bb0015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn510","article-title":"Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States","volume":"101","author":"Wheeler","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.ygyno.2020.06.493_bb0020","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ygyno.2020.06.493_bb0025","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"10103","key":"10.1016\/j.ygyno.2020.06.493_bb0030","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2020.06.493_bb0035","series-title":"Presented at the 107th Annual Meeting of the American Association for Cancer Research; April 16\u201320, 2016; New Orleans, LA. Abstract LB-095","article-title":"HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity","author":"Krupar","year":"2016"},{"issue":"30","key":"10.1016\/j.ygyno.2020.06.493_bb0040","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/j.vaccine.2009.04.041","article-title":"The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in volunteers with advanced carcinoma of the cervix","volume":"27","author":"Maciag","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ygyno.2020.06.493_bb0045","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ygyno.2003.10.045","article-title":"Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"92","author":"Muggia","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.06.493_bb0050","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00280-002-0470-2","article-title":"A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"50","author":"Plaxe","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.ygyno.2020.06.493_bb0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1023\/A:1026255403046","article-title":"A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study","volume":"21","author":"Armstrong","year":"2003","journal-title":"Investig. New Drugs"},{"issue":"1","key":"10.1016\/j.ygyno.2020.06.493_bb0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0090-8258(03)00253-1","article-title":"Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"90","author":"Fracasso","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.06.493_bb0065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ygyno.2005.09.009","article-title":"Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"100","author":"Brewer","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.06.493_bb0070","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2005.11.048","article-title":"Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"102","author":"Rose","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2020.06.493_bb0075","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/COC.0b013e31803377c8","article-title":"Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study","volume":"30","author":"Garcia","year":"2007","journal-title":"Am. J. Clan. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.06.493_bb0080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2008.03.009","article-title":"Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"110","author":"Miller","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2020.06.493_bb0085","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ygyno.2009.07.024","article-title":"A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"115","author":"Fiorica","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2020.06.493_bb0090","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/IGC.0b013e3181a83467","article-title":"A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study","volume":"19","author":"Schilder","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2020.06.493_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control. Clin. Trials"},{"issue":"3","key":"10.1016\/j.ygyno.2020.06.493_bb0100","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.06.493_bb0110","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2016.27.e51","article-title":"Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research","volume":"27","author":"Lee","year":"2016","journal-title":"J. Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2020.06.493_bb0115","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IGC.0000000000001235","article-title":"A randomized phase 2 study of ADXS11-001 Listeria monocytogenes-listeriolysin O immunotherapy with or without cisplatin in treatment of advanced cervical cancer","volume":"28","author":"Basu","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.06.493_bb0120","author":"NCCN"},{"key":"10.1016\/j.ygyno.2020.06.493_bb0125","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","article-title":"Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"22","author":"Moore","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.06.493_bb0130","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study","volume":"23","author":"Long","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.ygyno.2020.06.493_bb0135","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2020.06.493_bb0140","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11912-005-0007-z","article-title":"Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer","volume":"7","author":"Tewari","year":"2005","journal-title":"Curr. Oncol. Rep."},{"issue":"17","key":"10.1016\/j.ygyno.2020.06.493_bb0145","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820323179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820323179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:52:10Z","timestamp":1758772330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820323179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0090825820323179"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.493","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology\/gynecologic oncology group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.06.493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}